{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-197751","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2025-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.675523+00:00","generated_at":"2026-05-17T07:37:45.727142+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Dianthus reports positive Phase 2 MaGic trial for claseprubart in gMG; both doses meet endpoints","bullets":["Claseprubart 300mg Q2W: MG-ADL mean change -4.6 (placebo-adjusted -1.8, p=0.0113); QMG -4.4 (adj. -2.4, p=0.0144) at Week 13.","Claseprubart 600mg Q2W: MG-ADL mean change -5.4 (adj. -2.6, p=0.0006); QMG -4.5 (adj. -2.5, p=0.0111).","Rapid onset: both doses showed stat. significant MG-ADL and QMG improvement as early as Week 1.","Favorable safety: no related serious infections, SAEs, or discontinuations; no Boxed Warning or REMS anticipated for planned autoinjector.","Phase 3 gMG trial evaluating 300mg Q2W and Q4W vs placebo planned to start in 2026; CIDP and MMN data expected 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-197751","json":"https://secwatch.observer/filing/0001193125-25-197751.json","markdown":"https://secwatch.observer/filing/0001193125-25-197751.md","text":"https://secwatch.observer/filing/0001193125-25-197751.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/0001193125-25-197751-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:37:45.727142+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}